Subtype
Liver Carcinoma
CI-CAN-00001073Explore in graph →
783 active trials14 approved drugs17 evidence items
- NCIt
- C7927
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001073Explore in graph →
Clinical trials
3,367 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (386)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02210182 | A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma | completed | Phase 1 | 29 | Oncozyme Pharma Inc.INDUSTRY | 1 | Mar 14, 2016 | clinicaltrials |
| NCT01147380 | Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation(MIAMINK) | completed | Phase 1 | 18 | Seigo NishidaOTHER | 1 | Mar 10, 2016 | clinicaltrials |
| NCT02101593 | Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer | completed | Phase 1 | 8 | Polaris GroupINDUSTRY | 1 | Mar 4, 2016 | clinicaltrials |
| NCT01594125 | Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma | completed | Phase 1 | 30 | Boehringer IngelheimINDUSTRY | 1 | Feb 12, 2016 | clinicaltrials |
| NCT00712790 | Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 35 | Singapore Clinical Research InstituteOTHER | 4 | Jan 6, 2016 | clinicaltrials |
| NCT02578602 | MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer | completed | Phase 1 | 26 | University of Southern CaliforniaOTHER | 1 | Oct 19, 2015 | clinicaltrials |
| NCT00997022 | Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients | completed | Phase 1 | 14 | Columbia UniversityOTHER | 1 | Aug 10, 2015 | clinicaltrials |
| NCT00608361 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT01406574 | Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 23 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT00493883 | Use of TheraSphere® Yttrium-90 Glass Microspheres for Primary and Metastatic Liver Tumors | completed | Phase 1 / Phase 2 | 81 | Southwestern Regional Medical CenterOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT00844168 | Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant | completed | Phase 1 | 4 | University of WashingtonOTHER | 1 | Mar 27, 2015 | clinicaltrials |
| NCT00976170 | Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) | completed | Phase 1 | 42 | Chugai PharmaceuticalINDUSTRY | 2 | Oct 3, 2014 | clinicaltrials |
| NCT00978107 | Trial of TG4023 Combined With Flucytosine in Liver Tumors | completed | Phase 1 | 16 | TransgeneINDUSTRY | 1 | Jul 16, 2014 | clinicaltrials |
| NCT01540461 | Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC) | completed | Phase 1 | 17 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 8, 2014 | clinicaltrials |
| NCT01116635 | Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 24 | University of British ColumbiaOTHER | 1 | Mar 17, 2014 | clinicaltrials |
| NCT01129570 | Siliphos in Advanced Hepatocellular Carcinoma | completed | Phase 1 | 3 | Abby SiegelOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00956436 | Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 40 | BiogenINDUSTRY | 4 | Sep 16, 2013 | clinicaltrials |
| NCT01042041 | Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer | completed | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 26, 2013 | clinicaltrials |
| NCT01102400 | A Study of MEDI-575 in Patients With Advanced Solid Malignancies | completed | Phase 1 | 22 | AstraZenecaINDUSTRY | 1 | Feb 6, 2013 | clinicaltrials |
| NCT00028496 | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00047346 | Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00844623 | TK-based Suicide Gene Therapy for Hepatocellular Carcinoma | completed | Phase 1 | 10 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT01040559 | Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas | completed | Phase 1 | 18 | Centre Hospitalier Universitaire DijonOTHER | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00712855 | A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma(HCC) | completed | Phase 1 | 23 | Human Genome Sciences Inc., a GSK CompanyINDUSTRY | 1 | Oct 30, 2012 | clinicaltrials |
| NCT00614913 | Proton Beam Therapy for Treatment of Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 76 | Loma Linda UniversityOTHER | 1 | Aug 20, 2012 | clinicaltrials |
| NCT00802555 | Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 21 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 3 | Jul 12, 2012 | clinicaltrials |
| NCT00999882 | Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients | completed | Phase 1 | 26 | AstraZenecaINDUSTRY | 2 | Jul 10, 2012 | clinicaltrials |
| NCT00731445 | Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 43 | Zeria PharmaceuticalINDUSTRY | 1 | Jul 3, 2012 | clinicaltrials |
| NCT00662246 | Dose Escalation Study Using Proton Beam Radiotherapy for Hepatocellular Carcinoma | completed | Phase 1 | 24 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 3, 2012 | clinicaltrials |
| NCT00784290 | Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 35 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 26, 2012 | clinicaltrials |
| NCT00988195 | Study of Pegylated Human Recombinant Arginase for Liver Cancer | completed | Phase 1 | 15 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Mar 14, 2012 | clinicaltrials |
| NCT01092091 | Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002)(BCT-100-002) | completed | Phase 1 / Phase 2 | 20 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Mar 14, 2012 | clinicaltrials |
| NCT01131689 | Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma | completed | Phase 1 | 20 | Samsung Medical CenterOTHER | 1 | Feb 2, 2012 | clinicaltrials |
| NCT01031784 | Radioactive Holmium Microspheres for the Treatment of Liver Metastases(HEPAR) | completed | Phase 1 | 15 | UMC UtrechtOTHER | 1 | Jan 31, 2012 | clinicaltrials |
| NCT00073736 | Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 28 | Ligand PharmaceuticalsINDUSTRY | 3 | Aug 12, 2011 | clinicaltrials |
| NCT00882869 | XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 75 | Aegera TherapeuticsINDUSTRY | 1 | Jul 13, 2011 | clinicaltrials |
| NCT00437424 | A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction | completed | Phase 1 | 24 | Bristol-Myers SquibbINDUSTRY | 2 | May 4, 2011 | clinicaltrials |
| NCT00933816 | Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy(SILIUS) | completed | Phase 1 / Phase 2 | 37 | Kindai UniversityOTHER | 1 | Nov 25, 2010 | clinicaltrials |
| NCT00768937 | Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 22 | Medical University of ViennaOTHER | 1 | Nov 9, 2010 | clinicaltrials |
| NCT00478374 | Sorafenib With TACE to Treat Hepatocellular Carcinoma(S-TACE) | completed | Phase 1 | 21 | University of BernOTHER | 1 | Nov 2, 2010 | clinicaltrials |
| NCT00848094 | Radiation Dose Escalation Study for Advanced Liver Cancer | completed | Phase 1 | 40 | Fudan UniversityOTHER | 0 | Feb 20, 2009 | clinicaltrials |
| NCT00122876 | Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC) | completed | Phase 1 / Phase 2 | 25 | Light Sciences OncologyINDUSTRY | 3 | Dec 7, 2007 | clinicaltrials |
| NCT00534664 | Phase I/II Study of Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular Carcinoma(TheraBionic) | completed | Phase 1 / Phase 2 | 40 | University of Sao PauloOTHER | 1 | Sep 26, 2007 | clinicaltrials |
| NCT00479050 | Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm(TACE-RFA) | completed | Phase 1 | 291 | Shandong UniversityOTHER | 0 | May 25, 2007 | clinicaltrials |
| NCT00076609 | Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 31 | PhytoCeuticaINDUSTRY | 2 | Mar 28, 2007 | clinicaltrials |
| NCT00234182 | Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCC | completed | Phase 1 / Phase 2 | 84 | The University of Hong KongOTHER | 0 | Dec 1, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Mar 14, 2016source: clinicaltrials